A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population (STEP Study)

CKD Stage 4 Clinical Trial

Official title:

A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04633304
• Other study ID #: STP-001
• Status: Recruiting
• Phase: N/A
• Start date: December 15, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: February 2023
• Source: California Institute of Renal Research
• Contact: Osman Khawar, MD
• Phone: 7602943162
• Email: okhawar[@]bnmg.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an investigator-initiated post-marketing study that will evaluate use of the WaveLinQ system, a new and novel method of fistula creation using a percutaneous method in patients who require the creation of an arteriovenous fistula (AVF).

Description:

This investigator-initiated post-marketing study will evaluate use of the WaveLinQ system, a new and novel method of fistula creation, which uses a percutaneous method to create an AVF. Thirty male and female subjects with CKD 3-5 and who are clinical indicated for arteriovenous fistula (AVF) creation will be enrolled using the WaveLinQ device. Eligibility confirmation will be confirmed during screening up to 28 days from the index procedure. Subjects who are eligible will undergo fistula creation per standard institutional technique (index/baseline) and be followed at least monthly for 6 months per their standard of care plan. Primary, clinical and functional patency will be observed throughout the trial in addition to other data collection points per protocol. The expected total duration of subject participation from screening until the end of study is up to 7 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2023
• Est. primary completion date: December 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or Female Age of at least 18 years

2. CKD 3 through 5 as measured by GFR 45 and under by MDRD equation on two separate occasions at least 3 months apart.

3. Provide written informed consent using a form that is approved by the Institutional Review Board (IRB) prior to collection of study data or performance of study procedures.

4. Currently not on hemodialysis.

5. Life expectancy of at least one year

6. Meets Anatomical Criteria for EndoAVF creation via pre-procedure Duplex or Venography Vascular anatomy suitable for creation of the AV fistula

7. Willing to comply with the specified follow-up evaluations

Exclusion Criteria:

1. Anatomical exclusion criteria met

2. Thought to need dialysis within 30 days.

3. The subject is in a hypercoagulable state.

4. The subject has known bleeding diathesis.

5. The subject has insufficient cardiac output to support a native fistula in the opinion of the investigator.

6. Known history of active intravenous drug abuse.

7. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.

8. The subject has known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated.

9. Evidence of active infection on the day of the index procedure (temperature of = 38.0° Celsius and/ or WBC of = 12,000 cells/ µL, if collected).

Related Conditions & MeSH terms

• CKD Stage 3
• CKD Stage 4
• CKD Stage 5

Intervention

Device:
• EndoAVF System for endovascular AV fistula creation
AV fistula creation

Locations

Country	Name	City	State
United States	California Institute of Renal Research	Escondido	California

Sponsors (1)

Lead Sponsor	Collaborator
California Institute of Renal Research

Country where clinical trial is conducted

United States, 

References & Publications (6)

Berland TL, Clement J, Griffin J, Westin GG, Ebner A. Endovascular Creation of Arteriovenous Fistulae for Hemodialysis Access with a 4 Fr Device: Clinical Experience from the EASE Study. Ann Vasc Surg. 2019 Oct;60:182-192. doi: 10.1016/j.avsg.2019.02.023. — View Citation

Inston N, Khawaja A, Tullett K, Jones R. WavelinQ created arteriovenous fistulas versus surgical radiocephalic arteriovenous fistulas? A single-centre observational study. J Vasc Access. 2020 Sep;21(5):646-651. doi: 10.1177/1129729819897168. Epub 2020 Jan 2. — View Citation

Jones RG, Khawaja A, Tullett K, Inston NG. Early experience and observations in endovascular dialysis fistula re-intervention. J Vasc Access. 2020 Nov;21(6):818-825. doi: 10.1177/1129729819888374. Epub 2019 Dec 9. — View Citation

Lok CE, Rajan DK, Clement J, Kiaii M, Sidhu R, Thomson K, Buldo G, Dipchand C, Moist L, Sasal J; NEAT Investigators. Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Ac — View Citation

Radosa CG, Radosa JC, Weiss N, Schmidt C, Werth S, Hofmockel T, Plodeck V, Gatzweiler C, Laniado M, Hoffmann RT. Endovascular Creation of an Arteriovenous Fistula (endoAVF) for Hemodialysis Access: First Results. Cardiovasc Intervent Radiol. 2017 Oct;40(1 — View Citation

Zemela MS, Minami HR, Alvarez AC, Smeds MR. Real-World Usage of the WavelinQ EndoAVF System. Ann Vasc Surg. 2021 Jan;70:116-122. doi: 10.1016/j.avsg.2020.05.006. Epub 2020 May 15. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Procedure Success	Successful endoAVF creation confirmed by intraprocedural angiography or duplex Ultrasound post procedure	Interval of time from access placement until any intervention is undertaken to maintain or re-establish patency - 6 weeks
Secondary	Physiologically mature endoAVF at 6 months	Percent of patients who did not require any intervention to be undertaken to maintain or re-establish patency	6 months